Literature DB >> 24293074

Palliative treatment of metastatic colorectal cancer: what is the optimal approach?

John H Strickler1, Herbert I Hurwitz.   

Abstract

Worldwide, colorectal cancer (CRC) is responsible for over 600,000 deaths annually and remains a significant public health concern. Because of therapeutic advancements over the past two decades, patients with metastatic CRC are living longer with an improved quality of life. This review will highlight recent trial evidence that improves outcomes for patients with metastatic disease. Topics will include the optimal use of first-line combination chemotherapy, bevacizumab in patients with advanced age or comorbidities, maintenance chemotherapy, first-line use of anti-EGFR therapies, first-line cetuximab versus bevacizumab, anti-angiogenic therapies past progression, and management of treatment-refractory disease. Clinical trial evidence will be presented, along with guidance on how to integrate recent evidence into clinical practice. Finally, this review will examine innovative drug development strategies, and will discuss potentially actionable targets identified by molecular testing.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24293074     DOI： 10.1007/s11912-013-0363-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  54 in total

1.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

2.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Authors:  Niall C Tebbutt; Kate Wilson; Val J Gebski; Michelle M Cummins; Diana Zannino; Guy A van Hazel; Bridget Robinson; Adam Broad; Vinod Ganju; Stephen P Ackland; Garry Forgeson; David Cunningham; Mark P Saunders; Martin R Stockler; Yujo Chua; John R Zalcberg; R John Simes; Timothy J Price
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

3.  Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

Authors:  D Koeberle; D C Betticher; R von Moos; D Dietrich; P Brauchli; D Baertschi; K Matter; R Winterhalder; M Borner; S Anchisi; P Moosmann; A Kollar; P Saletti; A Roth; M Frueh; M Kueng; R A Popescu; S Schacher; V Hess; R Herrmann
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

4.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

6.  Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Authors:  C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem
Journal:  Ann Oncol       Date:  2007-12-06       Impact factor: 32.976

7.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

Authors:  Bert H O'Neil; Robert Allen; David R Spigel; Thomas E Stinchcombe; Dominic T Moore; Jordan D Berlin; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Authors:  James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553
View more
  4 in total

1.  S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).

Authors:  Yuji Miyamoto; Akihito Tsuji; Hiroaki Tanioka; Soichiro Maekawa; Hirofumi Kawanaka; Masaki Kitazono; Eiji Oki; Yasunori Emi; Hidetsugu Murakami; Yutaka Ogata; Hiroshi Saeki; Mototsugu Shimokawa; Shoji Natsugoe; Yoshito Akagi; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2016-01-08       Impact factor: 3.402

2.  First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

Authors:  Harpreet S Wasan; Peter Gibbs; Navesh K Sharma; Julien Taieb; Volker Heinemann; Jens Ricke; Marc Peeters; Michael Findlay; Andrew Weaver; Jamie Mills; Charles Wilson; Richard Adams; Anne Francis; Joanna Moschandreas; Pradeep S Virdee; Peter Dutton; Sharon Love; Val Gebski; Alastair Gray; Guy van Hazel; Ricky A Sharma
Journal:  Lancet Oncol       Date:  2017-08-03       Impact factor: 41.316

3.  Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer.

Authors:  Hui Sheng; Xiaoli Wei; Minjie Mao; Jincan He; Tianqi Luo; Shilin Lu; Liye Zhou; Zhixin Huang; Anli Yang
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

4.  Teng-Long-Bu-Zhong-Tang induces p21-dependent cell senescence in colorectal carcinoma LS174T cells via histone acetylation.

Authors:  Bing Hu; Hong-Mei An; Shuang-Shuang Wang; Jia-Lu Zheng; Xia Yan; Xiao-Wei Huang; Jian-Hui Tian
Journal:  J Exp Pharmacol       Date:  2017-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.